
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/8986/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:09:13 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--8986 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--8986 block--content--website-notice-block block--content--website-notice-block--8986 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--8986 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--8986 block--content--system-main-block block--content--system-main-block--8986 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--8986 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001104659-22-082822.rtf%3b%20filename_%3dUTF-8%27%270001104659-22-082822.rtf" type="application/rtf" title="0001104659-22-082822.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001104659-22-082822.pdf%3b%20filename_%3dUTF-8%27%270001104659-22-082822.pdf" type="application/pdf" title="0001104659-22-082822.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001104659-22-082822.xls%3b%20filename_%3dUTF-8%27%270001104659-22-082822.xls" type="application/vnd.ms-excel" title="0001104659-22-082822.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001104659-22-082822.html" type="application/octet-stream" title="0001104659-22-082822-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srrk="../../../scholarrock.com/20220726">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_srrk_scholarrock.com_20220726 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20220726_20220726 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001727196 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:EntityCentralIndexKey">0001727196</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="#srrk-20220726.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-07-26to2022-07-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-26</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION<br />
Washington, D.C. 20549</b></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_909_edei--DocumentType_c20220726__20220726_zk17BhhBtT21"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">CURRENT REPORT</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Date of Report (Date of earliest event Reported): <span id="xdx_906_edei--DocumentPeriodEndDate_c20220726__20220726_zO0ZGRvUsAg6"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 26, 2022</ix:nonNumeric></span>
</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 14pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20220726__20220726_z53nkF6tmnt"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:EntityRegistrantName">Scholar Rock Holding Corporation</ix:nonNumeric></span></b></span><br />
(Exact Name of Registrant as Specified in Charter)</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">
<tr style="vertical-align: top">
    <td style="width: 33%; text-align: center"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20220726__20220726_zpGl1svW7mF8"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 34%; text-align: center"><b><span id="xdx_90A_edei--EntityFileNumber_c20220726__20220726_zSl7qtQSfBvb"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:EntityFileNumber">001-38501</ix:nonNumeric></span></b></td>
    <td style="width: 33%; text-align: center"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20220726__20220726_zQOPuS1kZoQf"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:EntityTaxIdentificationNumber">82-3750435</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">(State or Other Jurisdiction of <br />
Incorporation)</td>
    <td style="text-align: center">(Commission File Number)</td>
    <td style="text-align: center">(I.R.S. Employer Identification <br />
Number)</td></tr>
<tr style="vertical-align: top">
    <td rowspan="1">&#160;</td>
    <td rowspan="1">&#160;</td>
    <td rowspan="1">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20220726__20220726_z1x61blCUgF3"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:EntityAddressAddressLine1">301 Binney Street</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20220726__20220726_z8eZXLQ71p35"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:EntityAddressAddressLine2">3rd Floor</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressCityOrTown_c20220726__20220726_z5eLv7i0s3Y"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:EntityAddressCityOrTown">Cambridge</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20220726__20220726_zz8N0w4O2r83"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20220726__20220726_zXo8kES6sgu3"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:EntityAddressPostalZipCode">02142</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">(Address of Principal Executive Offices) (Zip Code)</td></tr>
</table>
<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>(<span id="xdx_901_edei--CityAreaCode_c20220726__20220726_znloT4gvKbB7"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:CityAreaCode">857</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20220726__20220726_z9wqb2uKK7ob"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:LocalPhoneNumber">259-3860</ix:nonNumeric></span></b></span></p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Registrant's telephone
number, including area code)</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Former name or
former address, if changed since last report)</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #000000; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">
<tr style="vertical-align: top">
    <td style="width: 0.35in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_905_edei--WrittenCommunications_c20220726__20220726_z6GOUDDBbWXk"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_909_edei--SolicitingMaterial_c20220726__20220726_zUybFGUC8HNj"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementTenderOffer_c20220726__20220726_zrfIacMB945d"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20220726__20220726_zwzvO06DW6Ue"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt; vertical-align: top; width: 35%; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border: Black 1pt solid; padding: 1pt; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which <br />
registered</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20220726__20220726_zYiJyRsDzY08"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20220726__20220726_zdmeXZDF9ym4"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" name="dei:TradingSymbol">SRRK</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_edei--SecurityExchangeName_c20220726__20220726_zewFDfSYdgnb"> <ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>


<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR &#167;240.12b-2). Emerging growth company <span id="xdx_903_edei--EntityEmergingGrowthCompany_c20220726__20220726_zmvTYaUBp66j" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_909_edei--EntityExTransitionPeriod_c20220726__20220726_zCltvDM6w162"><ix:nonNumeric contextRef="From2022-07-26to2022-07-26" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 26, 2022, the Board of Directors (the &#8220;Board&#8221;)
of Scholar Rock Holding Corporation (the &#8220;Company&#8221;), upon the recommendation of its Nominating and Corporate Governance Committee,
increased the size of the Board to nine (9) directors and subsequently appointed Srinivas Akkaraju to join the Board filling the vacancy
created by the increase in the size of the Board. The Board determined that Dr. Akkaraju is independent under the listing standards of
NASDAQ and the Company&#8217;s corporate governance guidelines. Dr. Akkaraju will serve as a Class I director with a term expiring at
the annual meeting of stockholders to be held in 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a non-employee director, Dr. Akkaraju will receive cash compensation
and an equity award for his Board service, in accordance with the Company&#8217;s non-employee director compensation policy, as amended
from time to time. Dr. Akkaraju is not a party to any transaction with the Company that would require disclosure under Item 404(a) of
Regulation S-K, and there are no arrangements or understandings between Dr. Akkaraju and any other persons pursuant to which he was selected
as a director. In addition, Dr. Akkaraju will enter into an indemnification agreement with the Company consistent with the form of the
existing indemnification agreement entered into between the Company and its non-employee directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 26, 2022, the Company issued a press release announcing the
appointment of Dr. Akkaraju to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="1" style="font: 10pt Times New Roman, Times, Serif"><a href="#tm2221808d1_ex99-1.htm">99.1 Press Release issued by the Company on July 26, 2022, furnished hereto.</a></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; color: #0000ee">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="1" style="font: 10pt Times New Roman, Times, Serif">104 Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scholar Rock Holding Corporation</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 48%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July 26, 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span>&#160;&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Junlin Ho</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Junlin Ho</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Counsel &amp; Corporate Secretary</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>

<!-- Mirrored from investors.scholarrock.com/node/8986/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:09:14 GMT -->
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6PbTOH9judOgQp8gQ8bZsUYpbM9L690i+pXVDDIGQnPPlCBGKjFa6RobTosjhgE1bK4dQ4BkZTYneka43CfhZ4EVbx8q4bv2BKXkGPTMdjEt/75x3bbFKQM6GMh5GEmScTGKYb0Xw1VMyZ12hcVrVoEwFe6aWNTrFr/7DQT3JUPPqko7IVpNJYDSQvfyGSI4i2NFdPYivFvI8FUHYVSAyplv7jblZRw0sa2x8lu3Rfwcf3fxJGQ== -->
</XBRL>
<div><a name="tm2221808d1_ex99-1.htm"></a></div><HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Scholar Rock Announces the Addition of Srinivas
Akkaraju, M.D., Ph.D. to Its Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CAMBRIDGE, Mass.&mdash;July&nbsp;26, 2022&mdash; Scholar Rock (NASDAQ:
SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors
play a fundamental role, today announced that Dr.&nbsp;Srinivas Akkaraju, Founder and Managing General Partner at Samsara BioCapital,
has been appointed to Scholar Rock&rsquo;s Board of Directors as an independent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With over two decades of fundamentals-based, long term investment experience
in the biotechnology sector, Dr.&nbsp;Akkaraju will add valuable experience and insight to Scholar Rock&rsquo;s Board of Directors as
the company advances its late stage development pipeline and also invests in its robust discovery programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are thrilled to welcome Dr.&nbsp;Akkaraju to Scholar Rock&rsquo;s
Board of Directors as we continue to expand upon our diverse network of experienced biotechnology company-builders,&rdquo; said Nagesh
Mahanthappa, Ph.D., Founding Chief Executive Officer&nbsp;&amp; President of Scholar Rock. &ldquo;Dr.&nbsp;Akkaraju&rsquo;s deep understanding
of our scientific platform, our clinical programs and the complexities of the biotech capital markets, will be an invaluable addition
to our Board as we work diligently to accelerate our highly innovative therapeutic candidate for spinal muscular atrophy through its Phase
3 clinical trial and begin planning for our first potential commercial launch.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I have always been passionate about supporting innovation that
has transformative potential for patients and I am inspired by Scholar Rock&rsquo;s mission and data-driven approach making use of its
proprietary platform to modulate growth factors in the TGF&beta; superfamily to achieve differentiated pharmacology with huge therapeutic
potential,&rdquo; said Dr.&nbsp;Akkaraju. &ldquo;I have been closely following Scholar Rock&rsquo;s progress over several years, and I
am looking forward to partnering with the Board and the executive leadership team as we continue advancing the company&rsquo;s progress
towards improving the current standard of care for a range of serious diseases.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2017, Dr.&nbsp;Akkaraju founded Samsara BioCapital, where he currently
serves as Managing General Partner. A biotech investment fund that recently invested in Scholar Rock&rsquo;s completed registered direct
offering, Samsara is focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Prior
to Samara, Dr.&nbsp;Akkaraju held key strategic, leadership, operational, and advisory roles at various venture capital firms focusing
on the biopharmaceutical and life science industries, including Sofinnova Investment,&nbsp;Inc., New Leaf Venture Partners, and Panorama
Capital, LLC. Prior to co-founding Panorama Capital in 2005, he served as a Partner with J.P. Morgan Partners and advised on Business
and Corporate Development at Genentech,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<BR>
Dr.&nbsp;Akkaraju received his M.D. and a Ph.D. in Immunology from Stanford University and his undergraduate degrees in Biochemistry
and Computer Science from Rice University. He also serves as a director of Chinook Therapeutics,&nbsp;Intercept Pharmaceuticals, Syros
Pharmaceuticals, and Jiya Acquisition Corp. Previously, Dr.&nbsp;Akkaraju served as a director on the Boards of Seattle Genetics, Barrier
Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp., aTyr Pharma, and Amarin Corporation plc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Scholar Rock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock is a clinical-stage biopharmaceutical company focused
on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors
plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of
patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock&rsquo;s
approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery
and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing
product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting
growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more
efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and
LinkedIn (https://www.linkedin.com/company/scholar-rock/). Investors and others should note that we communicate with our investors and
the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and
FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well
as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information.
As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis.
The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock<SUP>&reg;</SUP> is a registered trademark of Scholar
Rock,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &quot;forward-looking statements&quot;
within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar
Rock&rsquo;s future expectations, plans and prospects, including without limitation, Scholar Rock&rsquo;s expectations regarding its growth,
strategy, and progress and indication selection and development timing, the ability of any individual to affect the growth, strategy,
and progress of Scholar Rock, and the potential of its product candidates and proprietary platform. The use of words such as &ldquo;may,&rdquo;
 &ldquo;might,&rdquo; &ldquo;could,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;future,&rdquo; &ldquo;potential,&rdquo;
or &ldquo;continue,&rdquo; and other similar expressions are intended to identify such forward-looking statements. All such forward-looking
statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These
risks and uncertainties include, without limitation, Scholar Rock&rsquo;s ability to provide the financial support, resources and expertise
necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock&rsquo;s nonclinical
and preclinical studies and clinical trials, and Scholar Rock&rsquo;s ability to manage expenses and to obtain additional funding when
needed to support its business activities, as well as those risks more fully discussed in the section entitled &quot;Risk Factors&quot;
in Scholar Rock&rsquo;s Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2022, as well as discussions of potential
risks, uncertainties, and other important factors in Scholar Rock&rsquo;s subsequent filings with the Securities and Exchange Commission.
Any forward-looking statements represent Scholar Rock&rsquo;s views only as of today and should not be relied upon as representing its
views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no
duty to update this information unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Scholar Rock:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors<BR>
Rushmie Nofsinger<BR>
</B></FONT>Scholar Rock<BR>
<U>rnofsinger@scholarrock.com</U><BR>
<U>ir@scholarrock.com</U><BR>
857-259-5573</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media<BR>
Ariane Lovell<BR>
</B></FONT>Finn Partners<BR>
<U>ariane.lovell@finnpartners.com</U><BR>
<U>media@scholarrock.com</U><BR>
917-565-2204</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Source:&nbsp;Scholar Rock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/8986\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
